OmniCyte is a preclinical Immunology company. Our therapeutics are developed on our proprietary, Targeted Immune Activating, platform technology. The platform activates an innate and an adaptive immune response through the dendritic cell that can be engineered to target numerous tumor types and pathogens.
Our human ovarian therapeutic (Omn007) has been successful in demonstrating a specific cytotoxic T-cell response with tumor infiltration that significantly inhibits tumor growth and activates t-cell memory. Proof of concept in ovarian cancer suggests the platform may be re-engineered to be effective against multiple solid tumors.
As published in Human Vaccines and Immunotherapies, 2022 and presented at the 2022 ISV Annual Congress, we have developed a highly effective COVID-19 Vaccine, which, stimulates a robust antibody response, T-cell activation, and does not require an adjuvant, and promises increased durability compared to existing vaccines. Additional infectious disease indications include many viral pathogens (prophylactic and therapeutic). OmniCyte has recently entered into two partnerships to develop vaccines for new indications.
Our human ovarian therapeutic (Omn007) has been successful in demonstrating a specific cytotoxic T-cell response with tumor infiltration that significantly inhibits tumor growth and activates t-cell memory. Proof of concept in ovarian cancer suggests the platform may be re-engineered to be effective against multiple solid tumors.
As published in Human Vaccines and Immunotherapies, 2022 and presented at the 2022 ISV Annual Congress, we have developed a highly effective COVID-19 Vaccine, which, stimulates a robust antibody response, T-cell activation, and does not require an adjuvant, and promises increased durability compared to existing vaccines. Additional infectious disease indications include many viral pathogens (prophylactic and therapeutic). OmniCyte has recently entered into two partnerships to develop vaccines for new indications.
Speaker
